Clinical Trial Opportunity for People Experiencing Symptoms Consistent With Secondary-Progressive MS (2)

People experiencing symptoms consistent with secondary-progressive multiple sclerosis may be eligible to participate in a clinical research trial of an investigational therapy, Siponimod.  A new Phase III clinical research trial, EXPAND, is looking for volunteers between 18 and 60 years of age, to participate in a trial of investigational daily oral medication. 

The EXPAND clinical research trial may not be appropriate for everyone. Researchers have identified specific criteria that participants must meet. Potentially eligible volunteers must undergo physical evaluation and have medical history reviewed by clinical trial personnel to determine eligibility.
This is a double-blind, placebo-controlled trial. Approximately one-third of participants will not receive active treatment with the study drug.
EXPAND = EXploring the efficacy and safety of Siponimod in PAtients with SecoNDary Progressive Multiple Sclerosis. For a link to the full advertisement for this trial, CLICK HERE.
If you are interested, please contact:
Kristina Bliss
This email address is being protected from spambots. You need JavaScript enabled to view it.